These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 29734190)

  • 1. Severe Pain Due to Paraspinal Abscess Formation in Two Patients with Squamous-Cell Carcinoma of the Head and Neck after Multimodal Treatment Including Cetuximab.
    Gerlach C; Pretzell I; Lieberknecht E; Mattyasovszky S; Weber M
    Oncol Res Treat; 2018; 41(6):395-398. PubMed ID: 29734190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concurrent cetuximab and postoperative radiation in resected high-risk squamous cell carcinomas of the head and neck: A single-institution experience.
    Araki D; Redman MW; Martins R; Eaton K; Baik C; Chow L; Goulart B; Lee S; Santana-Davila R; Liao J; Parvathaneni U; Laramore G; Futran N; Mendez E; Bhrany A; Rodriguez CP
    Head Neck; 2016 Sep; 38(9):1318-23. PubMed ID: 27061333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advanced Squamous Cell Carcinoma of the Head and Neck: The Current Role of Cetuximab.
    Granados-García M; Aguilar-Ponce JL; Maldonado-Magos F; De la Garza-Salazar JG
    ORL J Otorhinolaryngol Relat Spec; 2016; 78(6):320-333. PubMed ID: 28125819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose intensified hypofractionated intensity-modulated radiotherapy with synchronous cetuximab for intermediate stage head and neck squamous cell carcinoma.
    Thomson DJ; Ho KF; Ashcroft L; Denton K; Betts G; Mais KL; Garcez K; Yap BK; Lee LW; Sykes AJ; Rowbottom CG; Slevin NJ
    Acta Oncol; 2015 Jan; 54(1):88-98. PubMed ID: 25279959
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment patterns and outcomes among patients with recurrent/metastatic squamous cell carcinoma of the head and neck.
    Nadler E; Joo S; Boyd M; Black-Shinn J; Chirovsky D
    Future Oncol; 2019 Mar; 15(7):739-751. PubMed ID: 30511880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cetuximab with radiotherapy as an alternative treatment for advanced squamous cell carcinoma of the temporal bone.
    Ebisumoto K; Okami K; Hamada M; Maki D; Sakai A; Saito K; Shimizu F; Kaneda S; Iida M
    Auris Nasus Larynx; 2018 Jun; 45(3):637-639. PubMed ID: 28867454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidermal growth factor receptor (EGFR) pathway polymorphisms as predictive markers of cetuximab toxicity in locally advanced head and neck squamous cell carcinoma (HNSCC) in a Spanish population.
    Fernández-Mateos J; Seijas-Tamayo R; Mesía R; Taberna M; Pastor Borgoñón M; Pérez-Ruiz E; Adansa Klain JC; Vázquez Fernández S; Del Barco Morillo E; Lozano A; González Sarmiento R; Cruz-Hernández JJ;
    Oral Oncol; 2016 Dec; 63():38-43. PubMed ID: 27938998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The efficiency and adverse events of radiotherapy with cetuximab for Japanese head and neck cancer patients.
    Hirasawa K; Okamoto I; Motohashi R; Sato H; Takase S; Agata A; Takeda A; Tsukahara K
    Auris Nasus Larynx; 2017 Dec; 44(6):724-728. PubMed ID: 28237712
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epidermal growth factor receptor variant III in head and neck squamous cell carcinoma is not relevant for targeted therapy and irradiation.
    Thomas Koch D; Pickhard A; Gebel L; Buchberger AMS; Bas M; Mogler C; Reiter R; Piontek G; Wirth M
    Oncotarget; 2017 May; 8(20):32668-32682. PubMed ID: 28427242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse skin reactions during treatment with cetuximab plus radiotherapy: Multidisciplinary approach to minimize radio-chemotherapy interruption.
    Ricci F; Paradisi A; Silveri SL; Sampogna F; Miccichè F; Bonomo PL; DiNapoli N; Valentini V; Capizzi R; Guerriero C
    J Dermatolog Treat; 2015 Apr; 26(2):183-7. PubMed ID: 24852820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reirradiation with cetuximab in locoregional recurrent and inoperable squamous cell carcinoma of the head and neck: feasibility and first efficacy results.
    Balermpas P; Keller C; Hambek M; Wagenblast J; Seitz O; Rödel C; Weiss C
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(3):e377-83. PubMed ID: 22414284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. How Standard Is Second-Line Cetuximab in Recurrent or Metastatic Head and Neck Cancer in 2017?
    Szturz P; Seiwert TY; Vermorken JB
    J Clin Oncol; 2017 Jul; 35(20):2229-2231. PubMed ID: 28471725
    [No Abstract]   [Full Text] [Related]  

  • 13. Phase II trial of concurrent bio-chemoradiotherapy using docetaxel, cisplatin, and cetuximab for locally advanced head and neck squamous cell carcinoma.
    Nishimura G; Taguchi T; Takahashi M; Shiono O; Komatsu M; Sano D; Yabuki K; Arai Y; Takahashi H; Hata M; Oridate N
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1315-9. PubMed ID: 27154176
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of hyaluronic acid gel (Jalosome soothing gel) for the treatment of radiodermatitis in a patient receiving head and neck radiotherapy associated with cetuximab: A case report and review.
    Presta G; Puliatti A; Bonetti L; Tolotti A; Sari D; Valcarenghi D
    Int Wound J; 2019 Dec; 16(6):1433-1439. PubMed ID: 31475472
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cetuximab in the Context of Current Treatment of Squamous Cell Carcinoma of the Anus.
    Glynne-Jones R; Harrison M
    J Clin Oncol; 2017 Mar; 35(7):699-701. PubMed ID: 28068173
    [No Abstract]   [Full Text] [Related]  

  • 16. Cetuximab as treatment for head and neck cancer patients with a previous liver transplant: report of two cases.
    Holguin F; Rubió-Casadevall J; Saigi M; Marruecos J; Taberna M; Tobed M; Maños M; Mesía R
    J Chemother; 2017 Oct; 29(5):310-313. PubMed ID: 27380218
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and toxicity of cetuximab with chemotherapy in recurrent and metastatic head and neck cancer: A prospective observational study.
    Tiwari S; Goel V; John MC; Patnaik N; Doval DC
    Indian J Cancer; 2016; 53(4):487-492. PubMed ID: 28485336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation Between the Severity of Cetuximab-Induced Skin Rash and Clinical Outcome for Head and Neck Cancer Patients: The RTOG Experience.
    Bar-Ad V; Zhang QE; Harari PM; Axelrod R; Rosenthal DI; Trotti A; Jones CU; Garden AS; Song G; Foote RL; Raben D; Shenouda G; Spencer SA; Harris J; Le QT
    Int J Radiat Oncol Biol Phys; 2016 Aug; 95(5):1346-1354. PubMed ID: 27212198
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Functional Genomics Uncover the Biology behind the Responsiveness of Head and Neck Squamous Cell Cancer Patients to Cetuximab.
    Bossi P; Bergamini C; Siano M; Cossu Rocca M; Sponghini AP; Favales F; Giannoccaro M; Marchesi E; Cortelazzi B; Perrone F; Pilotti S; Locati LD; Licitra L; Canevari S; De Cecco L
    Clin Cancer Res; 2016 Aug; 22(15):3961-70. PubMed ID: 26920888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prolonged Overall Treatment Time and Lack of Skin Rash Negatively Impact Overall Survival in Locally Advanced Head and Neck Cancer Patients Treated with Radiotherapy and Concomitant Cetuximab.
    Roman J; Dissaux G; Gouillou M; Gobel Y; Potard G; Leclere JC; Conan-Charlet V; Gujral D; Abgral R; Guibourg B; Pradier O; Schick U
    Target Oncol; 2017 Aug; 12(4):505-512. PubMed ID: 28580506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.